New drug made available to ALS patients unable to join trials
Disease control
AVAILABLE
This expanded access program offers the drug tazbentetol to adults with ALS who cannot join other clinical studies. Participants take one 300 mg pill by mouth each day. The program aims to check the drug's safety and whether it helps control the disease.
Sponsor: Spinogenix • Aim: Disease control
Last updated Jun 27, 2026 14:03 UTC